Tesamorelin Production Cost Reports

The report provides a detailed analysis essential for establishing a tesamorelin production plant. It encompasses all critical aspects necessary for tesamorelin production, including the cost of tesamorelin production, tesamorelin plant cost, tesamorelin production costs, and the overall tesamorelin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tesamorelin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary gland to release natural growth hormone. It raises IGF-1 levels to target excess visceral abdominal fat. It is FDA-approved for subcutaneous injection (2 mg daily) in HIV-infected adults with lipodystrophy, reducing visceral adipose tissue. It improves lipid profiles and metabolic health without promoting muscle growth or general weight loss. It is also utilised for insulin resistance, non-alcoholic fatty liver disease, cognitive benefits, and fat quality improvements. Its common side effects include injection-site reactions, muscle and joint pain, oedema, elevated blood sugar, night sweats, nausea, rash, fatigue, and insomnia.

The market for tesamorelin is driven by the rising prevalence of HIV and associated lipodystrophy. The excess abdominal fat in treated patients, along with improved HIV survival rates, boosts its demand. The growing awareness in North America and rapid expansion in the Asia-Pacific through better diagnostics and access fuel its market. The innovations like Egrifta SV and WR formulations simplify dosing and storage, boosting adoption in hospitals, speciality clinics, and home care settings. The industrial tesamorelin procurement is influenced by its status as a speciality injectable biologic, patient assistance programs, and speciality pharmacy distribution. Also, reliable supply, competition from off-label peptides, regulatory approvals in expanding regions, and bulk tenders affect its sourcing.

Raw Material for Tesamorelin Production

According to the tesamorelin production plant project report, the key raw materials used in the production of tesamorelin include Rink Amide resin, Fmoc-amino acids, coupling activators (HBTU/HOBt), base (DIEA), and piperidine.

Production Process of Tesamorelin

The extensive tesamorelin production cost report consists of the following major industrial production process:

1. By Fmoc solid-phase peptide synthesis: The production of tesamorelin involves a Fmoc solid-phase peptide synthesis on Rink Amide resin. The assembling of a 44-amino acid chain from C-to-N terminus through sequential deprotection and coupling steps takes place. This is followed by the N-terminal attachment of the trans-3-hexenoyl group. The protected peptide is cleaved from resin using a TFA-based cocktail with scavengers, precipitated in diethyl ether, and washed to recover the crude product. The purified peptide is formulated with mannitol, sucrose, and histidine in water, sterile filtered into vials, lyophilised through freezing, primary/secondary drying under vacuum, then stoppered and sealed under nitrogen. Final batches undergo HPLC purity to get pure tesamorelin as the final product.

Tesamorelin is a synthetic 44-amino acid peptide analogue of growth hormone-releasing hormone (GHRH). It has a molecular formula of C221H366N72O67S (free base) or acetate salt form. It has a molecular weight of 5135.9 Da (free base) or ~5579 Da (acetate). It appears as a white to off-white amorphous powder soluble in water but only slightly in methanol. The modified N-terminal tyrosine with a trans-3-hexenoyl group enhances resistance to dipeptidyl peptidase. It is formulated as a lyophilised sterile powder for reconstitution to ~11.8 mg/mL at pH 5. It is stable at 2-8 degree Celsius with a subcutaneous half-life of 26-38 minutes.